Immunometabolism in microbial sepsis
微生物脓毒症的免疫代谢
基本信息
- 批准号:9722850
- 负责人:
- 金额:$ 19.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-15 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Project Summary/Abstract
Sepsis is the most common cause of mortality in many intensive care units and is responsible for more than
250,000 deaths in the United States annually. Microbial infection and trauma are the most common causes of
sepsis. Sepsis is characterized by an exaggerated innate immune response leading to a cytokine storm.
Recent studies suggest that activation of the innate immune cells causes vigorous metabolic changes towards
increased glucose utilization. Elevated glucose metabolism is also a common feature in the initial state of
sepsis. However, the role of glucose metabolism reprogramming in the regulation of innate immune function
and its relevance to sepsis is poorly understood. In this Proposal, we aim to study the role of two individual
glucose metabolism pathways in microbial sepsis, the hexosamine biosynthesis pathway (HBP) and the
pentose phosphate pathway (PPP). Our preliminary studies revealed essential roles of HBP-associated O-
GlcNAc (O-linked β-N-acetylglucosamine) signaling and PPP in antagonizing inflammatory response and
bacterial spreading, respectively. We further identified nuclear factor E2-related factor-2 (Nrf2) as a critical
mediator of both HBP and PPP pathways. Therefore, promoting the activities of HBP and PPP pathways
through pharmacological activation of Nrf2 may represent a promising therapeutic regimen for treating
microbial sepsis. We hypothesize that 1) HBP-associated O-GlcNAc signaling inhibits the innate immune
activation through O-GlcNAcylation of RIPK3 (receptor-interacting serine/threonine kinase 3); 2) PPP is
required for macrophage bacterial killing and host survival in sepsis by mediating caspase-1 activation; 3)
Genetic and pharmacological activation of these glucose metabolism pathways is effective in the treatment of
microbial sepsis. Cecal ligation and puncture-induced polymicrobial sepsis model will be employed to examine
the role and functions of glucose metabolism pathways. We will test whether dimethyl fumarate (DMF)
treatment plays a protective role in sepsis-induced mortality. The goal of the proposal is to examine the
function and mechanism of two glucose metabolism pathways on macrophage bacterial killing and
inflammation, both of which are key determinants of host survival. Results of these studies will provide novel
insights into the regulation and function of glucose metabolism signaling, which can potentially lead to the
identification of new therapeutic targets in the treatment of microbial sepsis.
项目摘要/摘要
脓毒症是许多重症监护病房中最常见的死亡原因,其原因超过
美国每年有25万人死亡。微生物感染和创伤是最常见的原因
败血症。败血症的特征是一种夸大的先天免疫反应,导致细胞因子风暴。
最近的研究表明,天然免疫细胞的激活会导致强烈的新陈代谢变化
提高葡萄糖利用率。糖代谢升高也是糖尿病初始状态的共同特征。
败血症。然而,糖代谢重编程在调节先天免疫功能中的作用
而它与脓毒症的相关性却知之甚少。在这项提案中,我们旨在研究两个人角色
微生物脓毒症中的葡萄糖代谢途径、氨基己糖生物合成途径(HBP)和
磷酸戊糖途径(PPP)。我们的初步研究揭示了HBP相关的O-
O-Linkedβ-N-乙酰氨基葡萄糖信号转导与PPP在抗炎反应中的作用
细菌的传播。我们进一步确定核因子E2相关因子-2(Nrf2)是一种关键的
HBP和PPP通路的中介物。因此,促进HBP和PPP途径的活性
通过药理作用激活NRF2可能是一种很有前途的治疗方案
微生物败血症。我们推测:1)HBP相关的O-GlcNAc信号抑制先天免疫
通过O-GlcN酰化RIPK3(受体相互作用的丝氨酸/苏氨酸激酶3)激活;2)PPP是
脓毒症中巨噬细胞杀菌和宿主生存所必需的;
这些葡萄糖代谢途径的遗传和药物激活在治疗糖尿病中是有效的。
微生物败血症。将采用盲肠结扎和穿刺法诱导的多菌败血症模型
葡萄糖代谢途径的作用和功能。我们将测试富马酸二甲酯(DMF)
治疗在脓毒症引起的死亡中起到保护作用。该提案的目标是研究
两种糖代谢途径对巨噬细胞杀菌作用及机制的研究
炎症,两者都是宿主生存的关键决定因素。这些研究的结果将提供新的
对糖代谢信号的调节和功能的洞察,这可能会导致
寻找治疗微生物败血症的新靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Haitao Wen其他文献
Haitao Wen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Haitao Wen', 18)}}的其他基金
Targeting immune inhibitory molecule SUSD2 to reverse immunosuppression
靶向免疫抑制分子SUSD2逆转免疫抑制
- 批准号:
10430219 - 财政年份:2021
- 资助金额:
$ 19.79万 - 项目类别:
Targeting immune inhibitory molecule SUSD2 to reverse immunosuppression
靶向免疫抑制分子SUSD2逆转免疫抑制
- 批准号:
10274585 - 财政年份:2021
- 资助金额:
$ 19.79万 - 项目类别:
Targeting immune inhibitory molecule SUSD2 to reverse immunosuppression
靶向免疫抑制分子SUSD2逆转免疫抑制
- 批准号:
10631911 - 财政年份:2021
- 资助金额:
$ 19.79万 - 项目类别:
Role and Mechanism of NLRX1-mediated Cell Stress Response in Insulin Resistance
NLRX1介导的细胞应激反应在胰岛素抵抗中的作用和机制
- 批准号:
8487694 - 财政年份:2013
- 资助金额:
$ 19.79万 - 项目类别:
相似国自然基金
碳-铁-微生物对滩涂围垦稻田土壤团聚体形成和稳定的调控机制
- 批准号:41977088
- 批准年份:2019
- 资助金额:61.0 万元
- 项目类别:面上项目
水热炭的微生物陈化(Microbial-aged Hydrochar)及其对稻田氨挥发的影响机制
- 批准号:41877090
- 批准年份:2018
- 资助金额:61.0 万元
- 项目类别:面上项目
微生物发酵过程的自组织建模与优化控制
- 批准号:60704036
- 批准年份:2007
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bio-Responsive and Immune Protein-Based Therapies for Inhibition of Proteolytic Enzymes in Dental Tissues
用于抑制牙齿组织中蛋白水解酶的基于生物响应和免疫蛋白的疗法
- 批准号:
10555093 - 财政年份:2023
- 资助金额:
$ 19.79万 - 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
- 批准号:
10582394 - 财政年份:2023
- 资助金额:
$ 19.79万 - 项目类别:
Malassezia and Candida auris: skin microbiome dysbiosis and de-regulation of cutaneous homeostasis
马拉色菌和耳念珠菌:皮肤微生物群失调和皮肤稳态失调
- 批准号:
10661959 - 财政年份:2023
- 资助金额:
$ 19.79万 - 项目类别:
Targeting host lipid metabolism to limit tissue damage in necrotizing fasciitis
靶向宿主脂质代谢以限制坏死性筋膜炎的组织损伤
- 批准号:
10639904 - 财政年份:2023
- 资助金额:
$ 19.79万 - 项目类别:
Commercialization Readiness Pilot (CRP) program support for: Direct-from-specimen identification of pathogens common in endocarditis
商业化准备试点 (CRP) 计划支持: 直接从样本鉴定心内膜炎常见病原体
- 批准号:
10758417 - 财政年份:2023
- 资助金额:
$ 19.79万 - 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
- 批准号:
10646578 - 财政年份:2023
- 资助金额:
$ 19.79万 - 项目类别:
Harnessing polymicrobial interactions in the catheterized urinary tract to identify novel inhibitors of Proteus mirabilis urease activity
利用插管尿路中的多种微生物相互作用来鉴定奇异变形杆菌尿素酶活性的新型抑制剂
- 批准号:
10678389 - 财政年份:2023
- 资助金额:
$ 19.79万 - 项目类别:
A Synergistic Multistrain Live Biotherapeutic Product for the Prevention and Treatment of Necrotizing Enterocolitis
用于预防和治疗坏死性小肠结肠炎的协同多菌株活生物治疗产品
- 批准号:
10761298 - 财政年份:2023
- 资助金额:
$ 19.79万 - 项目类别:
Bacterial CRISPR interference to define macrophage responses to group B Streptococcus proteins
细菌 CRISPR 干扰定义巨噬细胞对 B 族链球菌蛋白的反应
- 批准号:
10724607 - 财政年份:2023
- 资助金额:
$ 19.79万 - 项目类别:
Novel signaling molecules regulating platelet activation
调节血小板活化的新型信号分子
- 批准号:
10851106 - 财政年份:2023
- 资助金额:
$ 19.79万 - 项目类别:














{{item.name}}会员




